Myeloproliferative Neoplasms Clinical Trial
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
To evaluate efficacy, safety and pharmacokinetic profile of asciminib 40mg+imatinib or asciminib 60mg+imatinib versus continued imatinib and versus nilotinib versus asciminib 80mg in pre-treated patients with leukemia-cml/" >Chronic Myeloid Leukemia in chronic phase (CML-CP)
The study is a Phase 2, multi-center, open-label, randomized study of asciminib in two different doses (40 mg or 60 mg) in combination with imatinib 400 mg versus continued imatinib versus switch to nilotinib, versus asciminib 80mg single agent in subjects with chronic myeloid leukemia in chronic phase (CML-CP) who have been previously treated with imatinib first line therapy for at least one year and have not achieved deep molecular response (DMR). Eighty-four eligible subjects were randomized 1:1:1:1 to receive asciminib 60 mg once daily (QD) as add-on therapy to imatinib 400 mg QD, or 40 mg QD as add-on therapy to imatinib 400 mg QD, or to continue imatinib 400 mg QD, or to switch to nilotinib 300 mg twice a day (BID).
The asciminib single agent cohort will be conducted as an open label cohort. Approximately 20 eligible subjects will be enrolled to receive asciminib 80 mg QD.
An interim analysis was performed to gain an early insight into the safety and efficacy of the asciminib add-on combination. The interim analysis was planned to be performed when at least 40 (50%) patients have been randomized and have been followed for their 24 weeks visit assessment or have discontinued treatment. The interim analysis cut-off was on 22-July-2020. No change in study conduct were performed based on the benefit/risk balance.
This amendment aims to add an asciminib single agent cohort to assess whether asciminib single agent at the recommended dose of 80mg QD leads to similar efficacy and safety as observed in the add-on arms of asciminib and imatinib. This additional cohort will help to evaluate if the combination of asciminib with imatinib is needed to increase the likelihood of achieving DMR, or if this can be achieved by asciminib alone.
The primary analysis cut-off was on 10-Jan-2022. Eighty-four patients have been randomized in the study.
Subjects on the imatinib continuation arm who had not achieved MR4.5 at 48 weeks were allowed to cross-over (CO) to receive the add-on treatment within 4 weeks after week 48 visit. to receive the asciminib 60 mg combination add-on treatment, as this dose provided higher exposure. The cross-over is at the discretion of the investigator and the patient. Apart from a polymerase chain reaction (PCR) result of below MR4.5 at Week 48 visit, there are no other entry criteria for the cross-over part. Subjects on nilotinib are not allowed to cross- over to receive the add-on treatment.
Subjects on the study will continue on the allocated treatment until treatment failure, intolerability, or for up to 96 weeks (in arms 1 to 4) / or 48 weeks (in asciminib single agent cohort) after the last randomized subject received the first dose of treatment. After the last dose received, every subject will be followed up for safety for 30 days.
Male or female patients ≥ 18 years of age with a confirmed diagnosis of Chronic Myeloid Leukemia in chronic phase (CML-CP).
Minimum of one year (12 calendar months) treatment with imatinib first line for CML-CP (patients have to be on imatinib 400 mg QD at randomization and had no dose change in the past three months).
For Korea only: (i)a minimum of one year (12 calendar months) of prior treatment with imatinib for patients with BCR-ABL levels > 0.1%, ≤ 1% IS at the time of randomization. (ii) a minimum of two years (24 calendar months) of prior treatment with imatinib for patients with BCR-ABL levels > 0.01%, ≤ 0.1% IS at the time of randomization.
BCR-ABL1 levels > 0.01% IS (International Scale) and ≤ 1% IS at the time of randomization as confirmed with a central assessment at screening; patients must not have achieved deep molecular response (MR4 IS) confirmed by 2 consecutive tests at any time during prior imatinib treatment. An isolated, single test result with BCR-ABL1 levels < 0.01 % (MR4 IS) is allowed, however, it should not have been observed within the 9 months prior to randomization
Patient must meet the following laboratory values before randomization:
Absolute Neutrophil Count ≥ 1.5 x 10E9/L
Platelets ≥ 75 x 10E9/L
Hemoglobin ≥ 9 g/dL
Serum creatinine < 1.5 mg/dL
Total bilirubin ≤ 1.5 x ULN (Upper Limit of Normal) except for patients with Gilbert's syndrome who may only be included with total bilirubin ≤ 3.0 x ULN
Aspartate transaminase (AST) ≤ 3.0 x ULN
Alanine transaminase (ALT) ≤ 3.0 x ULN
Alkaline phosphatase ≤ 2.5 x ULN
Serum lipase ≤ 1.5 x ULN
Patients must have the following laboratory values ≥ Lower Limit of Normal or corrected to within normal limits with supplements prior to randomization: potassium increase of up to 6.0 mmol/L is acceptable if associated with creatinine clearance within normal limits ; calcium increase of up to 12.5 mg/dl or 3.1 mmol/L is acceptable if associated with creatinine clearance* within normal limits) ; magnesium increase up to 3.0 mg/dL or 1.23 mmol/L if associated with creatinine clearance within normal limits.
Key Exclusion Criteria:
Treatment failure according to European Leukemia Network (ELN) criteria 2013 during imatinib treatment.
Known second chronic phase of CML after previous progression to Accelerated Phase (AP)/Blast Crisis (BC).
Previous treatment with any tyrosine kinese inhibitors (TKIs) other than imatinib.
History or current diagnosis of ECG abnormalities indicating significant risk or safety for subjects participating in the study such as:
History of myocardial infarction, angina pectoris, coronary artery bypass graft within 6 months prior to randomization
Concomitant clinically significant arrhythmias
Resting QTcF ≥ 450 msec (male) or ≥ 460 msec (female) prior to randomization
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
Risk factors for Torsades de Pointes
Concomitant medications with a "known" risk of Torsades de Pointes
inability to determine the QTcF interval
Severe and/or uncontrolled concurrent medical disease that in the opinion of the investigator could cause unacceptable safety risks or compromise compliance with the protocol (e.g. uncontrolled diabetes, active or uncontrolled infection, uncontrolled clinically significant hyperlipidemia and high serum amylase)
History of acute pancreatitis within 1 year prior to randomization or medical history of chronic pancreatitis; on-going acute liver disease or history of chronic liver disease
History of other active malignancy within 3 years prior to randomization with the exception of basal cell skin cancer, indolent prostate cancer and carcinoma in situ treated curatively.
Other protocol defined inclusion/exclusion may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 46 Locations for this study
Augusta Georgia, 30912, United States More Info
*see various departments*
Chicago Illinois, 60637, United States More Info
Baltimore Maryland, 21205, United States
Baltimore Maryland, 21229, United States
Stony Brook New York, 11794, United States
Houston Texas, 77030, United States
Darlinghurst New South Wales, 2010, Australia
Adelaide South Australia, 5000, Australia
Melbourne Victoria, 3000, Australia
Graz , 8036, Austria
Wien , 1140, Austria
Montreal Quebec, H1T 2, Canada
Temuco Araucania, 48008, Chile
Vina del Mar Valparaiso, 25403, Chile
Brno - Bohunice , 625 0, Czechia
Copenhagen , DK-21, Denmark
Bordeaux , 33076, France
Mannheim Baden-Wuerttemberg, 68305, Germany
Berlin , 13353, Germany
Dresden , 01307, Germany
Hong Kong , , Hong Kong
Bologna BO, 40138, Italy
Milano MI, 20162, Italy
Roma RM, 00161, Italy
Shinagawa ku Tokyo, 141 8, Japan
Uijeongbu si Gyeonggi Do, 11759, Korea, Republic of
Seoul Seocho Gu, 06591, Korea, Republic of
Seoul , 03080, Korea, Republic of
Krakow , 31 53, Poland
Warszawa , 02 77, Poland
Wroclaw , 50 36, Poland
Lisboa , 1099 , Portugal
Porto , 4200-, Portugal
Moscow , 12516, Russian Federation
Moscow , 12528, Russian Federation
Saint Petersburg , 19102, Russian Federation
Saint Petersburg , 19734, Russian Federation
Sevilla Andalucia, 41009, Spain
Las Palmas de Gran Canaria , 35010, Spain
Madrid , 28034, Spain
Valencia , 46026, Spain
Changhua , 50006, Taiwan
Taipei , 10002, Taiwan
Taoyuan , 33305, Taiwan
Wirral Merseyside, CH63 , United Kingdom
London , W12 0, United Kingdom
Oxford , OX3 7, United Kingdom
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.